A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114 administered as monotherapy or in combination with selected standard of care (SOC) regimens.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Biopharma S.P.R.L.; UCB Biopharma SRL
• Treatments: Fluorouracil; Leucovorin; Trifluridine

Criteria

Inclusion Criteria:

• Participant must be at least 18 years of age inclusive, at the time of signing the informed consent

• Participant has advanced disease (ie, locally advanced or metastatic)

• Participant has measurable or non-measurable disease as defined by the relevant Response Evaluation Criteria in Solid Tumors (RECIST)

• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

Part A specific:

• Participant has a histologically and/or cytologically confirmed diagnosis of one of the following advanced solid tumor types: colorectal adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma, prostate adenocarcinoma, stomach adenocarcinoma, bladder urothelial carcinoma, or breast invasive carcinoma

Part B and C specific:

• Participant has a histologically and/or cytologically confirmed diagnosis of one of the following advanced solid tumor types: colorectal adenocarcinoma, gastric adenocarcinoma, or adenocarcinoma of the gastroesophageal junction

Exclusion Criteria:

• Participant has a known hypersensitivity to any components of the study medications or comparable drugs

• Active and clinically significant bacterial, fungal, or viral infection, known infections with hepatitis B, hepatitis C, known human immunodeficiency virus, or acquired immunodeficiency syndrome related illness

• Symptomatic central nervous system (CNS) malignancy or metastases. Screening of symptomatic participants without history of CNS metastases is not required. Participants with asymptomatic CNS lesions should have completed standard therapy for their CNS lesions prior to study enrolment

• Current hematologic malignancies

• Prior organ or allogeneic stem-cell transplantation

• QT interval corrected (QTc) >450 msec for male participants or QTc >470 msec for female participants or QTc >480 msec in participants with bundle branch block

• Participant has impaired renal function

• Alanine transaminase or AST are ≥2xULN (if liver metastases are present: ≥5xULN)

• Participant has moderate or severe cardiovascular disease

• Current or chronic history of liver disease or known hepatic or biliary abnormalities other than liver metastases